Elzein, Safa
Bao, Fei
Lin, Ray
Schnickel, Gabriel
Lowy, Andrew M.
Botta, Gregory P. http://orcid.org/0000-0001-9606-4508
Funding for this research was provided by:
National Cancer Institute (LRP KYGF9753)
National Center for Advancing Translational Sciences (KL2TR001112)
Article History
Received: 28 April 2021
Accepted: 9 August 2021
First Online: 3 September 2021
Declarations
:
: This study was performed in accordance with UCSD Institutional Review Board and ethical guidelines for data analysis and for any investigational treatments for which patients gave consent. The patient provided both written and verbal consent to participate in this manuscript.
: Patients involved in this case were consented for publication under the UCSD PREDICT Consent to Act as a Research Subject (#130794).
: Gregory Botta serves on the Advisory Board of Natera and as a consultant to TumorGen Inc. and CEND Therapeutics.